Ongoing episode of major depressive disorder is not associated with elevated plasma levels of kynurenine pathway markers

Psychoneuroendocrinology

Volumn 56, Issue , 2015, Pages 12-22

  Dahl, Johan ^a   Andreassen, Ole A ^b,c   Verkerk, Robert ^d   Malt, Ulrik Fredrik ^b,e   Sandvik, Leiv ^c   Brundin, Lena ^f,g   Ormstad, Heidi ^h  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g VAN ANDEL RESEARCH INSTITUTE   (United States)

^h UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

Author keywords

IDO; Inflammation; Kynurenic acid; Kynurenine; Major depressive disorder; Quinolinic acid

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; KYNURENIC ACID; KYNURENINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; QUINOLINIC ACID; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR DEPRESSION; MALE; MELANCHOLIA; METABOLITE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RECURRENT DISEASE; SIGNAL TRANSDUCTION; ADOLESCENT; BLOOD; MIDDLE AGED; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOKINES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; INTERVIEW, PSYCHOLOGICAL; KYNURENINE; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUINOLINIC ACID; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TRYPTOPHAN; YOUNG ADULT;

EID: 84927712616     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.02.011     Document Type: Article

References (46)

1. Bay-Richter C., Linderholm K.R., Lim C.K., Samuelsson M., Traskman-Bendz L., Guillemin G.J., Erhardt S., Brundin L. A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality. Brain Behav. Immun. 2015, 43:110-117.
2. Belmaker R.H., Agam G. Major depressive disorder. N. Engl. J. Med. 2008, 358:55-68.
3. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., Miller A.H. Interferon-alpha-induced changes in tryptophan metabolism, relationship to depression and paroxetine treatment. Biol. Psychiatry 2003, 54:906-914.
4. Chopra K., Kumar B., Kuhad A. Pathobiological targets of depression. Expert Opin. Ther. Targets 2011, 15:379-400.
5. Dahl J., Ormstad H., Aass H.C., Malt U.F., Bendz L.T., Sandvik L., Brundin L., Andreassen O.A. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 2014, 45:77-86.
6. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 2007, 21:153-160.
7. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
8. de Carvalho L.P., Bochet P., Rossier J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem. Int. 1996, 28:445-452.
9. Elovainio M., Hurme M., Jokela M., Pulkki-Raback L., Kivimaki M., Hintsanen M., Hintsa T., Lehtimaki T., Viikari J., Raitakari O.T., Keltikangas-Jarvinen L. Indoleamine 2,3-dioxygenase activation and depressive symptoms: results from the Young Finns Study. Psychosom. Med. 2012, 74:675-681.
10. Erhardt S., Lim C.K., Linderholm K.R., Janelidze S., Lindqvist D., Samuelsson M., Lundberg K., Postolache T.T., Traskman-Bendz L., Guillemin G.J., Brundin L. Connecting inflammation with glutamate agonism in suicidality. Neuropsychopharmacology 2013, 38:743-752.
11. Gabbay V., Klein R.G., Katz Y., Mendoza S., Guttman L.E., Alonso C.M., Babb J.S., Hirsch G.S., Liebes L. The possible role of the kynurenine pathway in adolescent depression with melancholic features. J. Child Psychol. Psychiatry 2010, 51:935-943.
12. Gal E.M., Sherman A.D. l-Kynurenine: its synthesis and possible regulatory function in brain. Neurochem. Res. 1980, 5:223-239.
13. Hamon M., Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 45:54-63.
14. Herve C., Beyne P., Jamault H., Delacoux E. Determination of tryptophan and its kynurenine pathway metabolites in human serum by high-performance liquid chromatography with simultaneous ultraviolet and fluorimetric detection. J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 1996, 675:157-161.
15. Heyes M.P., Achim C.L., Wiley C.A., Major E.O., Saito K., Markey S.P. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 1996, 320(Pt. 2):595-597.
16. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 2001, 21:7463-7473.
17. Hughes M.M., Carballedo A., McLoughlin D.M., Amico F., Harkin A., Frodl T., Connor T.J. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav. Immun. 2012, 26:979-987.
18. Kim Y.K., Na K.S., Shin K.H., Jung H.Y., Choi S.H., Kim J.B. Cytokine imbalance in the pathophysiology of major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1044-1053.
19. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 2012, 36:764-785.
20. Leonard B.E. The concept of depression as a dysfunction of the immune system. Curr. Immunol. Rev. 2010, 6:205-212.
21. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:702-721.
22. Maes M., Stevens W.J., Declerck L.S., Bridts C.H., Peeters D., Schotte C., Cosyns P. Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: further evidence for an inflammatory process during that illness. Prog. Neuropsychopharmacol. Biol. Psychiatry 1993, 17:241-255.
23. Miyaoka H., Otsubo T., Kamijima K., Ishii M., Onuki M., Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am. J. Psychiatry 1999, 156:1120.
24. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K., Nemeroff C.B., Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344:961-966.
25. Myint A.M., Bondy B., Baghai T.C., Eser D., Nothdurfter C., Schule C., Zill P., Muller N., Rupprecht R., Schwarz M.J. Tryptophan metabolism and immunogenetics in major depression: a role for interferon-gamma gene. Brain Behav. Immun. 2013, 31:128-133.
26. Myint A.M., Kim Y.K. Network beyond IDO in psychiatric disorders: revisiting neurodegeneration hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 48:304-313.
27. Myint A.M., Kim Y.K., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 2007, 98:143-151.
28. Neumeister A., Nugent A.C., Waldeck T., Geraci M., Schwarz M., Bonne O., Bain E.E., Luckenbaugh D.A., Herscovitch P., Charney D.S., Drevets W.C. Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch. Gen. Psychiatry 2004, 61:765-773.
29. Okuda S., Nishiyama N., Saito H., Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J. Neurochem. 1998, 70:299-307.
30. Ormstad H., Verkerk R., Aass H.C., Amthor K.F., Sandvik L. Inflammation-induced catabolism of tryptophan and tyrosine in acute ischemic stroke. J. Mol. Neurosci. 2013, 51:893-902.
31. Ormstad H., Verkerk R., Amthor K.F., Sandvik L. Activation of the kynurenine pathway in the acute phase of stroke and its role in fatigue and depression following stroke. J. Mol. Neurosci. 2014, 54:181-187.
32. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol. Psychiatry 2009, 66:522-526.
33. Quak J., Doornbos B., Roest A.M., Duivis H.E., Vogelzangs N., Nolen W.A., Penninx B.W., Kema I.P., de Jonge P. Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms?. Psychoneuroendocrinology 2014, 45:202-210.
34. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
35. Saito K., Nowak T.S., Markey S.P., Heyes M.P. Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J. Neurochem. 1993, 60:180-192.
36. Simon N.M., McNamara K., Chow C.W., Maser R.S., Papakostas G.I., Pollack M.H., Nierenberg A.A., Fava M., Wong K.K. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur. Neuropsychopharmacol. 2008, 18:230-233.
37. Sluzewska A., Rybakowski J., Bosmans E., Sobieska M., Berghmans R., Maes M., Wiktorowicz K. Indicators of immune activation in major depression. Psychiatry Res. 1996, 64:161-167.
38. Smith R.S. The macrophage theory of depression. Med. Hypotheses 1991, 35:298-306.
39. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 1993, 45:309-379.
40. Stone T.W., Behan W.M., Jones P.A., Darlington L.G., Smith R.A. The role of kynurenines in the production of neuronal death, and the neuroprotective effect of purines. J. Alzheimers Dis. 2001, 3:355-366.
41. Sublette M.E., Galfalvy H.C., Fuchs D., Lapidus M., Grunebaum M.F., Oquendo M.A., Mann J.J., Postolache T.T. Plasma kynurenine levels are elevated in suicide attempters with major depressive disorder. Brain Behav. Immun. 2011, 25:1272-1278.
42. Turnell D.C., Cooper J.D. Automated sequential process for preparing samples for analysis by high-performance liquid chromatography. J. Chromatogr. 1987, 395:613-621.
43. Walker A.K., Budac D.P., Bisulco S., Lee A.W., Smith R.A., Beenders B., Kelley K.W., Dantzer R. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013, 38:1609-1616.
44. Wichers M.C., Koek G.H., Robaeys G., Verkerk R., Scharpe S., Maes M. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 2005, 10:538-544.
45. Yuan W., Collado-Hidalgo A., Yufit T., Taylor M., Varga J. Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: selective inhibition of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA synthetase gene expression. J. Cell. Physiol. 1998, 177:174-186.
46. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.